1. - Longest available outcomes data with LUPKYNIS will be presented virtually during American College of Rheumatology (ACR) Convergence 2021; final results expected by the end of 2021 –

    - Updated interim analysis shows sustained safety and tolerability of LUPKYNIS compared with placebo -

    - Individuals treated with LUPKYNIS sustained meaningful reductions in proteinuria with stable eGFR at 30 months -

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced updated interim results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™ (voclosporin) for the treatment of…

    View Full Article
  2. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (the "Company") today announced that it will release its third quarter 2021 financial results on Wednesday, November 3, 2021, before the markets open. Aurinia's management team will also host a conference call at 8:30 a.m. ET to discuss the Company's financial results and provide general operational and business updates.

    The conference call and webcast is scheduled for November 3, 2021 8:30 a.m. ET. To participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia's website.

    View Full Article
  3. Data to highlight the safety, tolerability and efficacy of LUPKYNIS in patients with lupus nephritis

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) for the treatment of people with lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE) resulting in potentially life-threatening damage to the kidneys, will be presented at American Society of Nephrology (ASN) Kidney Week 2021 and at American College of Rheumatology (ACR) Convergence 2021. ASN Kidney Week will take place virtually on November 2-7 and ACR Convergence will…

    View Full Article
  4. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (the "Company") today announced that members of the senior management team will present at the following upcoming virtual investor conferences:

    • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Monday, September 20, 2021 at 2:55 pm ET. (access here)
    • Cantor Global Healthcare Conference on September 30, 2021 at 12:40 pm ET. (access here)

    In order to participate in the audio webcasts, interested parties can also register and access presentations under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcasts will be available on Aurinia's website.

    ABOUT AURINIA

    Aurinia is a fully integrated biopharmaceutical company…

    View Full Article
  5. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (the "Company") today announced that members of the senior management team will participate in the H.C. Wainwright & Co. 23rd Annual Global Investment Conference, September 13-15, 2021. The Aurinia presentation will be available on-demand beginning September 13, 2021 at 3 pm ET.

    The audio webcast is available here. Interested parties can also register and access the presentation under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia's website.

    ABOUT AURINIA

    Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are…

    View Full Article